PRTN3 and rheumatoid arthritis: Our finding that abatacept inhibits ACPA- and RF-mediated cytokine production in monocytes provides an attractive explanation for both clinical observations—its rapid anti-inflammatory effects as well as its preferential clinical efficacy in patients with RA with high-titer autoantibodies.